Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
World J Surg Oncol ; 9: 60, 2011 May 26.
Article in English | MEDLINE | ID: mdl-21615935

ABSTRACT

Gastrointestinal stromal tumors (GISTs) are rare mesenchymal neoplasms of the gastrointestinal tract (1%), and stomach is the most common location involved. However, the co-existence of gastric adenocarcinoma and GIST is very rare. A case of an 80-year-old male with a simultaneous presentation of a gastric adenocarcinoma and GIST is presented. Various hypotheses have been proposed in order to explain this rare simultaneous development, but even though it's cause has not been proven yet.


Subject(s)
Adenocarcinoma/diagnosis , Gastrointestinal Stromal Tumors/diagnosis , Neoplasms, Multiple Primary/diagnosis , Stomach Neoplasms/diagnosis , Adenocarcinoma/surgery , Aged, 80 and over , Antineoplastic Agents/therapeutic use , Benzamides , Gastrointestinal Stromal Tumors/drug therapy , Gastrointestinal Stromal Tumors/surgery , Humans , Imatinib Mesylate , Male , Neoplasms, Multiple Primary/therapy , Piperazines/therapeutic use , Pyrimidines/therapeutic use , Stomach Neoplasms/surgery
2.
World J Oncol ; 2(3): 143-146, 2011 Jun.
Article in English | MEDLINE | ID: mdl-29147239

ABSTRACT

Taxanes, both paclitaxel and doxetaxel are the medication of the future in the management of solid tumors. In high risk breast cancer patients, the combination of concurrent paclitaxel and docetaxel chemotherapy with adjuvant radiotherapy is an attractive option to sequential treatment, with potential for enforcing both local and systemic control. This case report examines the tolerance of such treatment. A 54-year-old Greek woman without a relevant medical history, presented with clinical diagnosed breast cancer staged T4NxM0. Neo-adjuvant chemotherapy was initially administered, and paclitaxel was administered concurrently with radiotherapy in order to achieve local control. During the third cycle of paclitaxel the patient developed grade III dermatitis. The tumor showed a reduction in size by 70%, however, chronic cutaneous and subcutaneous changes have not been accessed. In conclusion, adjuvant breast cancer therapy with concurrent standard dose radiotherapy and paclitaxel (175 mg/m2) every three weeks, should be approached cautiously owing to paclitaxel induced dermatitis.

SELECTION OF CITATIONS
SEARCH DETAIL
...